Information Provided By:
Fly News Breaks for August 10, 2016
MYGN
Aug 10, 2016 | 06:29 EDT
Wells Fargo analyst Tim Evans downgraded Myriad Genetics to Market Perform saying the company's hereditary franchise "is eroding more rapidly than we foresaw." The analyst cut his price target range for the shares to $20-$22 from $42-$45. Piper Jaffray and Barclays also downgraded Myriad this morning.
News For MYGN From the Last 2 Days
MYGN
I agree to the thefly.com's disclaimer & terms of use
About Privacy Terms of Use

© 1996-2018 TheStreet, Inc., 14 Wall Street, 15th Fl, NY, NY 10005

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.